The landscape of supermarket offerings in the UK is evolving rapidly, especially with the emergence of a new health-focused trend: 'Jab-uary.' While initiatives like Veganuary and Dry January continue to promote plant-based diets and abstinence from alcohol, this year's buzz centers around a more controversial front — products tailored for individuals on weight-loss medications, particularly the expensive GLP-1 receptor agonists such as Wegovy and Mounjaro. But here's where it gets controversial: many supermarkets are now launching special ranges and marketing campaigns aimed at consumers using these drugs, raising questions about societal perceptions of dieting, health, and transparency.
Major chains including Marks & Spencer, Morrisons, Asda, Ocado, and the Co-op are notably targeting shoppers who utilize these injectable weight-loss treatments. These drugs, often referred to broadly as GLP-1 agonists, are increasingly mainstream; it's estimated that around 6% of UK adults are now using them, according to market analyst Jonny Forsyth from Mintel. Despite their rising popularity, Forsyth suggests that the excitement around these medications is disproportionately influencing consumer behavior, fueling trends like high-protein diets and low-calorie choices even among those not on medication.
And this is the part most people miss: in recent holiday retail updates, some major retailers reported noticeable changes in shopping patterns. For example, Greggs CEO Roisin Currie noted that customers were opting for smaller portions and healthier options, reflecting a shift in how people perceive and approach their food choices. Similarly, Sainsbury’s has observed more consumers moving toward fresh, high-fiber, healthier foods, prompting the grocery chain to introduce low-calorie, high-protein ready meals such as its 'Small but Mighty' range, priced around £3 for a 300g portion.
In the online space, Ocado has created a dedicated 'weight management' aisle featuring products compatible with GLP-1 treatments. Their curated selection includes everything from small 100g steak servings costing about £3.50 to premium powders like AG1 greens supplement, priced at £107 per pack. The supermarket reports strong demand for protein-rich staples like chicken, cottage cheese, sports drinks, and dietary supplements.
The focus on nutrient-dense options is echoed by other retailers as well. M&S has launched a 'Nutrient Dense' range, which claims to pack high nutritional value per calorie. For example, their £7 chicken satay meal and the £2 coconut water shot 'H₅O' are marketed as ideal for those reducing their food intake, emphasizing convenience without sacrificing nutrient quality. Meanwhile, the Co-op promotes 'mini meals' inspired by global cuisines, priced at around £3.50 for portions generally weighing between 250 to 280 grams.
However, supermarket executives and analysts debate whether these small portions and specialized ranges truly offer added value to consumers. Charlotte Derra, a consumer goods expert, highlights that while the pricing appears competitive overall, the cost per kilo of GLP-1 friendly meals can be significantly higher—by as much as 35% compared to larger, non-specialized options. For instance, Morrisons’ GLP-1 friendly meals like chicken casserole weigh just 280g and cost about £3.75, but when assessed on a per-gram basis, they incur a premium.
Further complicating matters, companies like M&S, Co-op, and Iceland are carefully avoiding explicitly labeling their products with 'GLP-1' branding on packaging — a tactical move to sidestep potential stigma, as Forsyth notes. This reluctance to openly associate products with medication use reflects consumers' privacy concerns and their potential reluctance to openly admit to using these drugs.
Nevertheless, the mix of pricing, marketing strategies, and consumer perceptions raises important questions. Are these small, nutrient-dense portions genuinely meeting a market need, or are they simply a response to economic pressures and shrinking household budgets? The broader context involves persistent issues like shrinkflation — where shoppers get less product for the same amount of money — which fosters suspicion among consumers.
Some industry experts believe that the trend towards smaller, health-oriented portions may be a strategic response from supermarkets trying to adapt to changing consumer preferences amid a competitive, £250 billion UK grocery market. Mark Whalley of Explners comments that the real challenge is persuading shoppers that smaller portions are beneficial, especially when the price per unit often favors larger packages. The fundamental question remains: do consumers genuinely prefer these targeted, smaller-sized products, or would they simply eat less of what they already purchase if price and portion size were more transparent?
In the end, whether supermarkets are innovating in health-conscious food options with small portions as a genuine benefit or just another marketing ploy in a challenging market remains a topic ripe for debate. What’s your take — are these new offerings a step forward for health-conscious consumers, or just another twist in the ongoing saga of price manipulation and consumer skepticism? Share your thoughts below.
